%0 Journal Article
%T Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3
%A Vigani
%A Aline Gonzalez
%A Gon£¿ales
%A Eduardo Sellan
%A Pavan
%A Maria Helena Postal
%A Genari
%A Flavia
%A Tozzo
%A Raquel
%A Lazarini
%A Maria Silvia Kroll
%A Fais
%A Viviane
%A Feltrin
%A Adriana
%A Gon£¿ales
%A Neiva Sellan
%A Gon£¿ales Jr
%A Fernando Lopes
%J Brazilian Journal of Infectious Diseases
%D 2012
%I Brazilian Society of Infectious Diseases
%R 10.1590/S1413-86702012000300003
%X background: pegylated interferon (peg-ifn) and standard interferon (ifn) play a significant role in the treatment of hepatitis c virus (hcv) infection. biosimilar standard ifn is widely available in brazil for the treatment of hcv infection genotypes 2 or 3, but its efficacy compared to peg-ifn is unknown. objective: to compare the sustained virological response (svr) rates following treatment with biosimilar standard ifn plus ribavirin (rbv) versus peg-ifn plus rbv in patients with hcv genotypes 2 or 3 infection. methods: a retrospective cohort study was conducted in patients with hcv genotypes 2 or 3 infection treated with biosimilar standard ifn plus rbv or with peg-ifn plus rbv. svr rates of the two treatments were compared. results: from january 2005 to december 2010, 172 patients with a mean age of 44 +/- 9.3 years were included. there were eight (4.7%) patients with hcv genotype 2 infections. one hundred fourteen (66.3%) were treated with biosimilar standard ifn plus rbv, whist 58 (33.7%) patients were treated with peg-ifn plus rbv. between the two groups, there were no significant differences regarding age, gender, glucose level, platelet count, hepatic necroinflammatory grade, and hepatic fibrosis stage. overall, 59.3% (102/172) patients had svr. in patients treated with peg-ifn plus rbv, 79.3% (46/58) had svr compared to 49.1% (56/114) among those treated with biosimilar standard ifn plus rbv (p = 0.0001). conclusion: in patients with hcv genotypes 2 or 3 infection, a higher svr was observed in patients receiving peg-ifn plus rbv related to patients treated with biosimilar standard ifn plus rbv.
%K interferons
%K hepatitis c
%K treatment outcome.
%U http://www.scielo.br/scielo.php?script=sci_abstract&pid=S1413-86702012000300003&lng=en&nrm=iso&tlng=en